Literature DB >> 18486036

Handbook of anti-tuberculosis agents. Introduction.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18486036     DOI： 10.1016/S1472-9792(08)70002-7

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN： 1472-9792            Impact factor:   3.131


× No keyword cloud information.
  23 in total

1.  Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.

Authors:  Todd J Zurlinden; Garrett J Eppers; Brad Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.

Authors:  Claudia Sala; Neeraj Dhar; Ruben C Hartkoorn; Ming Zhang; Young Hwan Ha; Patricia Schneider; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

3.  System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis.

Authors:  Xingji Zheng; Yossef Av-Gay
Journal:  J Vis Exp       Date:  2017-04-05       Impact factor: 1.355

4.  Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice.

Authors:  Rahul Kumar Verma; Willem A Germishuizen; M Portia Motheo; Atul Kumar Agrawal; Amit Kumar Singh; Mradul Mohan; Pushpa Gupta; Umesh Datta Gupta; Moloko Cholo; Ronald Anderson; P Bernard Fourie; Amit Misra
Journal:  Antimicrob Agents Chemother       Date:  2012-11-26       Impact factor: 5.191

5.  Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.

Authors:  Santiago Ramón-García; Carol Ng; Hilary Anderson; Joseph D Chao; Xingji Zheng; Tom Pfeifer; Yossef Av-Gay; Michel Roberge; Charles J Thompson
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

6.  Steady-state population pharmacokinetics of terizidone and its metabolite cycloserine in patients with drug-resistant tuberculosis.

Authors:  Mwila Mulubwa; Pierre Mugabo
Journal:  Br J Clin Pharmacol       Date:  2019-07-12       Impact factor: 4.335

7.  Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains.

Authors:  Leah E Lim; Catherine Vilchèze; Carol Ng; William R Jacobs; Santiago Ramón-García; Charles J Thompson
Journal:  Antimicrob Agents Chemother       Date:  2012-11-19       Impact factor: 5.191

8.  PharmGKB summary: isoniazid pathway, pharmacokinetics.

Authors:  Daniel J Klein; Sotiria Boukouvala; Ellen M McDonagh; Scott R Shuldiner; Nicola Laurieri; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

9.  Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides.

Authors:  Santiago Ramón-García; Ralf Mikut; Carol Ng; Serge Ruden; Rudolf Volkmer; Markus Reischl; Kai Hilpert; Charles J Thompson
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

10.  Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients.

Authors:  Patricia Sheen; Melissa Méndez; Robert H Gilman; Lizeth Peña; Luz Caviedes; Mirko J Zimic; Ying Zhang; David A J Moore; Carlton A Evans
Journal:  J Clin Microbiol       Date:  2009-06-17       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.